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Abstract
Background: The mechanisms of immune response are structured within a highly complex regulatory system.
Genetic associations with variation in the immune response to rubella vaccine have typically been assessed one
locus at a time. We simultaneously assessed the associations between 726 SNPs tagging 84 candidate immune
response genes and rubella-specific antibody levels. Blood samples were obtained from 714 school-aged children
who had received two doses of MMR vaccine. Associations between rubella-specific antibody levels and 726
candidate tagSNPs were assessed both one SNP at a time and in a variety of multigenic analyses.
Results: Single-SNP assessments identified 4 SNPs that appeared to be univariately associated with rubella
antibody levels: rs2844482 (p = 0.0002) and rs2857708 (p = 0.001) in the 5’UTR of the LTA gene, rs7801617 in the
5’UTR of the IL6 gene (p = 0.0005), and rs4787947 in the 5’UTR of the IL4R gene (p = 0.002). While there was not
significant evidence in favor of epistatic genetic associations among the candidate SNPs, multigenic analyses
identified 29 SNPs significantly associated with rubella antibody levels when selected as a group (p = 0.017). This
collection of SNPs included not only those that were significant univariately, but others that would not have been
identified if only considered in isolation from the other SNPs.
Conclusions: For the first time, multigenic assessment of associations between candidate SNPs and rubella
antibody levels identified a broad number of genetic associations that would not have been deemed important
univariately. It is important to consider approaches like those applied here in order to better understand the full
genetic complexity of response to vaccination.
Background
The importance of developing protective humoral
immunity following vaccination is widely recognized, as
those who fail to respond are at increased risk of con-
tracting the disease if exposed. Rubella is well controlled
via vaccination programs in industrialized countries, but
epidemics of the disease occasionally occur in develop-
ing countries and both rubella virus infection and con-
genital rubella syndrome remain a major health concern
around the world [1,2]. Understanding how host genetic
influences modify response to rubella immunization
may shed light into the biology of immunity to rubella
infection, as well as into the potential development of
even more highly effective vaccines. While the heritabil-
ity of antibody responses to rubella vaccination has been
estimated to be as high as 46% [3], knowledge of the
genetic control of rubella vaccine-induced immunity
remains incomplete.
Our group and others have shown that polymorph-
isms in the human leukocyte antigen (HLA) region, as
well as SNPs in cytokine and cytokine receptor genes,
are associated with differences in a variety of immune
responses to rubella vaccine, but do not explain all of
the variance in immune responses seen within the popu-
lation [4-16]. Studies with other viral vaccines, such as
measles and mumps, have demonstrated associations
between cytokine and cytokine receptor gene poly-
morphisms and immune responses [17,18]. Because of
the central role of cytokines as intercellular protein mes-
s e n g e r sa n dt h er o l eo ft h e i rr e c e p t o r si nt h ei m m u n e
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polymorphisms may significantly influence the outcome
of rubella vaccine immune response. For example, poly-
morphisms in both coding and noncoding regions of
these genes can affect multiple aspects of cytokine biol-
ogy, such as transcriptional activity protein production,
receptor binding and functional activity [19,20]. Thus, a
wide variety of genes is likely to be important in regulat-
ing immune response to live viral vaccines.
While the role of cytokines in antiviral immune
responses has been established, little is known about
how other gene families control immune responses to
rubella virus. Studies in a variety of other models
(viruses, bacteria, microbial antigens) have also recently
demonstrated the importance of innate and vitamin
receptor genes in regulating immune responses [21-23].
In this regard, innate antiviral factor TRIM, toll-like
receptors (TLR) and their associated intracellular signal-
ing molecules activation is critical to stimulating innate
and adaptive immunity [24]. Importantly, innate path-
ways detect infection and serve two purposes: mediate
initial anti-viral response and prime more powerful and
specific adaptive responses. Finally, vitamins and their
receptors are known to have hormone-like attributes
and were also found to affect innate and adaptive immu-
nity [11,25]. To further characterize the impact of
immune gene polymorphisms on variability in vaccine-
induced humoral immunity, it is crucial to broadly
examine variants in key genes important to the immune
response to viral vaccines such as rubella. The genetic
diversity of innate, adaptive, antiviral effector and other
immune response genes has not been comprehensively
studied within the context of rubella vaccine-induced
humoral immune responses.
The discovery of genetic variations caused by single
nucleotide polymorphisms (SNPs) has led to population-
based immunogenetic studies intended to elucidate the
potential relationship between host genomic variation
and immune response [26]. A high level of regulatory
complexity is required in the human immune system to
insure a high probability of functional redundancy in
both cell-mediated and humoral immune responses to
vaccination [27,28]. For instance, one gene may be able
to compensate for potential loss of function due to
genetic variation in another. This would lead to reduced
power to detect real associations because variation in
immune response may only be apparent within subjects
with genetic variants in both of the genes. Because such
associations could be missed with single SNP analyses,
when associations between genetic variants and mea-
sures of immune response are studied it is important to
examine more than just their relationships with indivi-
dual SNPs. That is, not only should genetic associations
be studied for the main effects of single genetic variants
on immune response, but multigenic associations,
whether epistatic or otherwise, should be examined as
well [29,30]. A growing collection of approaches is
becoming available for the study of multigenic associa-
tions in association with disease states. These include
relatively standard statistical approaches to study inter-
actions, but also newer approaches that have been
designed to search for the presence of multigenic effects
in high dimensional genetic data consisting of many
SNPs [31-38].
In this study, we searched for evidence of multigenic
associations among a broad collection of SNPs identified
from non-HLA genes that are candidates for being
immunologically relevant to the development of a
humoral response to rubella vaccination after two doses
of measles-mumps-rubella vaccine. Due to the large
number of genes in immune response gene families, we
selected a group of key genes for each family, which,
based on biologic plausibility and the published litera-
ture, are highly likely to be involved in regulating rubella
immunity. We were particularly interested in assessing
the degree to which the inclusion of multilocus associa-
tions would identify important genetic variation that
contributes to rubella-specif i ca n t i b o d yl e v e l s .T od a t e ,
no such data have been published to address this issue.
Results
We attempted to genotype a total of 768 SNPs in a
cohort of 738 children who had received two doses of
rubella vaccine. After SNPs with call rates below 90%,
H W Ep - v a l u e sl e s st h a n0 . 0 0 1o rm i n o ra l l e l ef r e q u e n -
cies less than 5% were excluded from analysis, a total of
726 remained, for an overall genotyping success rate of
94.5%. Subject exclusions were made on the basis of
poor DNA quality (n = 6), complete genotyping failure
(n = 4) and call rates below 95% (n = 14). These exclu-
sions removed 24 subjects, leaving 714 subjects for ana-
lysis. Data from these individuals are summarized in
Table 1. Included with these summaries are the associa-
tions between the various descriptive variables and
rubella antibody levels. Of note, differences in antibody
levels were observed between males and females (p =
0.009), and among categories defined by the age at
which the second rubella vaccination was received (p =
0.001).
Figure 1 contains a quantile plot of the single-SNP
p-values, each assessed individually. This figure suggests
that there are a number of SNPs associated with rubella
antibody levels. In particular, the top four SNPs stand
out as being the most likely to be univariately associated
with antibody levels, although their p-values were not
smaller than the cut-off corresponding to a Bonferroni
correction for 726 statistical tests. These SNPs were
rs2844482 (p = 0.0002) and rs2857708 (p = 0.001) in
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the IL6 gene (p = 0.0005), and rs4787947 in the 5’UTR
of the IL4R gene (p = 0.002). The minor allele of each
of these SNPs was associated with increasing levels of
rubella-specific antibody.
Our omnibus test of association between the number
of positively associated alleles carried across all of these
candidate SNPs and the observed antibody levels sug-
gested that, even with the high number of null SNPs
apparent from the univariate analyses, there was a sig-
nificant association between this collection of SNPs and
rubella antibody after performing a randomization test
to account for multiple comparisons (p = 0.029). In
order to narrow the list of SNPs that contributed to this
omnibus association, we performed a stepwise selection
procedure. This procedure identified a list of 29 SNPs
that all contributed to the genetic association with
r u b e l l aa n t i b o d yl e v e l sw h e nc o n s i d e r e ds i m u l t a n e o u s l y
in the same regression model, with a global p-value
obtained via a randomization test of 0.017. These SNPs
are illustrated in Table 2. The SNP with the smallest
p-value in the univariate analyses, rs2844482, also had
the smallest p-value after adjusting for the other SNPs
in the multi-allelic model. Interestingly, several SNPs
without a clear ordinal trend in univariate analyses were
significantly associated with the outcome on a per-allele
basis after controlling for other SNPs in candidate
multi-allelic model. One example of this is rs1800795,
which displayed a u-shaped trend across the three geno-
types when examined individually (p = 0.511), and dis-
played a negative dose-response after controlling for
other SNPs in the multi-allelic model (Allelic Fold-
change, 95% CI: 0.79, 0.71-0.88, p < 0.001).
The plot in Figure 2 represents the results from the
analysis of the associations between the 263,175 possible
Table 1 Characteristics of the study population and their associations with rubella-specific IgG antibody levels
(reported in IU/ml)
Variable Level Number of subjects Median Q1 - Q3
a P-value
b
Overall 714 34.5 19.2 - 63.7
Age at enrollment (years) 11-13 212 37.0 19.1 - 67.1 0.967
14-15 190 34.8 19.4 - 58.5
16-17 200 33.3 19.2 - 70.2
18-19 112 34.5 19.2 - 57.9
Age at first rubella vaccination (months) ≤14 89 35.4 19.6 - 59.9 0.556
15 384 31.4 19.0 - 62.2
16-17 119 41.2 18.9 - 72.6
≥18 122 39.9 21.8 - 66.2
Age at second rubella vaccination (years) ≤5 205 27.6 16.6 - 55.3 0.001
6-10 109 37.0 20.5 - 69.6
11 122 34.9 18.9 - 65.4
≥12 278 39.9 22.1 - 69.7
Gender Female 336 39.9 20.0 - 69.7 0.009
Male 378 30.9 18.3 - 56.7
Race Other 65 33.4 17.7 - 62.9 0.903
White 649 34.5 19.2 - 63.7
Notes:
a Q1 and Q3 represent the first (25
th percentile) and third (75
th percentile) quartiles, respectively.
b p-value represents a test of the null hypothesis that there are no differences in the level of rubella antibody IgG levels among the categories represented.
Figure 1 Quantile plot of observed versus expected p-values
(on the logarithmic scale) for single-SNP associations with
rubella antibody levels. The points in the upper right hand side of
the plot that are distant from the line of unity correspond to the
SNPs with the strongest evidence for association.
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levels. The observed p-values deviate somewhat from
the line of unity, but not in a way that is indicative of
t h ep r e s e n c eo fas m a l ln u m b e ro fp a i r so fS N P st h a t
are strongly associated with rubella antibody levels. In
fact, the smallest p-value of 1.07 × 10
-5 for the combina-
tion of rs10489626, an intronic SNP in IL12RB2, and
rs1420094, a 3’ flanking SNP in IL18R1, was actually
less extreme than what would be expected if there were
no pair-wise epistatic associations present.
As with the assessment of all possible pair-wise inter-
actions, the use of recursive partitioning algorithms did
not yield strong evidence in favor of major epistatic
interactions. After forming the recursive partitioning
tree, an assessment of the degree of pruning required to
avoid over-fitting indicated that the best-fitting tree was
one with a single node, with the split being on
rs7801617. Because of this finding, further analyses seek-
ing additional multi-allelic epistatic effects were not
pursued.
Table 2 SNP associations identified through the model selection procedure, sorted from the smallest to the largest
multi-SNP p-value.












rs2844482 LTA 5’UTR 15.5 32(18.6-59.3) 41.2(21.3-72.6) 72.5(41.5-108.7) 0.000 0.164 0.027 <0.001
rs1880241 IL6 5’UTR 49.1 30.1(17.6-59) 36.2(19.8-67.6) 40.3(20.3-68.2) 0.014 0.133 0.024 <0.001
rs2243248 IL4 5’UTR 7.3 36.2(19.4-66.2) 27.8(16.5-56.2) 17.9(17.8-129.9) 0.023 -0.182 0.036 <0.001
rs1800795 IL6 5’UTR 42.8 37.2(19.2-70.1) 32.6(19-61.4) 39.9(19.4-63.1) 0.511 -0.102 0.025 <0.001
rs2256965 LST1 intron 42.9 36.3(18.8-66.7) 33.9(18.6-64.5) 32.6(21.2-59.4) 0.891 0.085 0.021 <0.001
rs4787947 IL4R 5’UTR 8.7 32.7(18.4-62.4) 43.2(26.4-68.8) 79.4(48.5-107) 0.002 0.119 0.029 <0.001
rs2227284 IL4 intron 31.1 31.8(18.9-60.1) 37.9(19.6-69.5) 38.1(18.3-69.7) 0.179 0.081 0.020 <0.001
rs1800629 TNF 5’UTR 17.4 33.7(19.2-61.7) 39.5(19.6-73.5) 31.2(21.8-68.2) 0.132 0.104 0.026 <0.001
rs9610 IL10RA 3’UTR 44.1 39.9(21.3-69.7) 33.2(18.6-66.3) 29.6(18.3-52.4) 0.004 -0.064 0.017 <0.001
rs2256774 IL2RA intron 33.8 33.6(18.1-59.2) 33.1(19.5-64.5) 42.8(26.1-78.7) 0.016 0.064 0.017 <0.001
rs9427092 ADAR 3’UTR 22.7 33.3(19-61.1) 34.8(19.5-67.5) 40.3(22.8-83.2) 0.102 0.069 0.021 0.001
rs2243300 IL4 5’UTR 8.3 33.8(19-63.3) 37.7(20.1-63.7) 46.7(29.1-262.1) 0.252 0.100 0.032 0.002
rs1153592 RARB intron 16.4 36.6(19.6-65.4) 31.1(18.1-60.1) 41.4(20.5-61.1) 0.079 -0.067 0.023 0.003
rs228979 IL2RB intron 26.0 37.3(20.6-66.5) 31.2(18-59.7) 25.9(18.8-67.6) 0.048 -0.053 0.019 0.005
rs3091338 IL3 3’UTR 38.2 33.3(18.2-60.6) 33.6(19.5-63.1) 39.8(20.7-72.3) 0.100 0.049 0.018 0.006
rs12757998 RNASEL 3’UTR 28.0 33.4(18.8-58.9) 37(19.6-68.3) 35.5(18.7-72.6) 0.130 0.052 0.019 0.006
rs1732778 OAS2 3’UTR 25.1 32.9(19.2-57.4) 38.4(19.1-71.7) 37.8(19.3-74.8) 0.036 0.052 0.019 0.007
rs4648212 EIF2AK2 intron 6.5 36.7(19.5-65) 27.6(16.6-52) 22.7(20.5-23.6) 0.018 -0.087 0.033 0.008
rs2229857 ADAR coding 27.4 31.2(18-63) 40.3(20.5-65) 39.1(21.5-64.5) 0.072 0.049 0.019 0.011
rs17882988 TNFRSF1B intron 17.3 34(18.8-62) 33.3(19.7-64.5) 67.8(33.2-108.1) 0.183 0.055 0.022 0.011
rs3740996 TRIM5 coding 10.7 37.3(19.6-68.2) 27.3(17.6-56.2) 39.8(21.1-81.9) 0.016 -0.069 0.027 0.011
rs2246614 MUPCDH coding 34.9 36.3(20-68.2) 32.9(18.9-60.1) 35.3(17.7-64.6) 0.202 -0.043 0.018 0.014
rs2179 TRIM22 intron 30.0 37.4(19.6-66.3) 33.5(18.2-64.8) 26.8(17.2-46.7) 0.039 -0.044 0.018 0.015
rs2287350 EIF2AK2 intron 38.1 33.3(19.5-68.3) 36.1(19-67.2) 31.1(18.8-53.1) 0.057 -0.041 0.017 0.018
rs1422876 IL12B 5’UTR 48.9 31(17.9-66.2) 36.9(19.6-63.7) 36.3(19.5-62.2) 0.200 0.040 0.017 0.018
rs2226299 IFNAR1 intron 18.6 33.2(19.2-62.9) 35(18.2-67.6) 39.1(28.2-60.1) 0.308 0.049 0.021 0.022
rs6793694 RARB intron 37.7 37.4(19.9-66.5) 33.3(18.8-63.1) 32.7(17.3-56.8) 0.039 -0.040 0.018 0.023
rs11064145 SCNN1A 3’UTR 42.5 28.4(17.9-61.1) 39.7(20.6-67.6) 36.5(19.1-60.1) 0.100 0.038 0.017 0.024
rs12626735 TMEM50B 3’UTR 21.1 38.4(19.6-69.7) 29.6(18.3-55.8) 31.2(18.9-59.1) 0.013 -0.045 0.020 0.030
Identified SNPs are all significant when adjusting for all other SNPs shown in the table, and for the descriptive variables outlined in Table 1. Univariate results are
shown for comparison.
Notes:
a Q1 and Q3 represent the first and third quartiles, the 25
th and 75
th percentiles, respectively.
b Estimate represents the difference in log(antibody level) associated with carrying one copy of the minor allele. The anti-log of this quantity provides an
estimate of the fold-change in antibody levels associated with carrying one copy of the minor allele.
c S.E. represents the standard error of the Estimate. The ratio of the Estimate to the S.E. provides a measure of the relative strength of the effect among the SNPs
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Because of the regulatory complexity of immune
responses to complex antigens, there is almost certainly
a diversity of genes that together influence the immune
response to vaccination. While there are many genes
that are strong candidates, the bulk of those that have
an effect on the levels of rubella-specific antibody raised
in response to immunization have yet to be identified.
In this study, we examined a broad collection of SNPs
that tag 84 genes that have been identified as potentially
playing a role in the immune process. We have per-
formed an array of analyses in an attempt to identify
potential multigenic associations between these candi-
date SNPs and the observed levels of rubella-specific
antibody levels following MMR-II vaccination.
As we have reported previously, a number of SNPs
and HLA alleles have already been identified as being
univariately associated with variation in responses to
rubella immunization [7-16]. In the analyses presented
h e r e ,w ew e r ea b l et oe x a m i n ea l lu n i v a r i a t eS N Pa s s o -
ciations with rubella antibodies simultaneously. This
assessment suggested that the top four SNPs were
among those that were significantly associated with the
humoral immune response. When broader analyses
were performed that explicitly searched for multiple
SNPs that independently contributed to variation in
rubella antibody levels while statistically correcting for
multiple testing using a randomization approach, we
found that there was a significant association between
the number of positively associated alleles carried by an
individual across all candidate SNPs and differences in
rubella antibody level (p = 0.029). In order to identify
the subset of SNPs that captured this signal, we subse-
quently performed a SNP selection procedure and iden-
tified a total of 29 SNPs that simultaneously provided
information on the levels of rubella-specific antibodies
(p = 0.017). In both of these analyses, we employed
resampling procedures to account for the process of
model building and selection as the tests for significance
were performed [39].
We performed two separate analyses in our search for
epistatic effects among the 726 SNPs. We first assessed
the significance of all possible two-way combinations of
SNPs (263,175 statistical tests). While there were more
SNP pairs with p-values between 0.01 and 0.0001 than
would have been expected under the null hypothesis, we
found that the smallest p-value was actually larger than
what would be expected under the hypothesis that no
SNP pairs were significantly associated with rubella anti-
body levels. Likewise, as we performed a recursive parti-
tioning analysis, we found that the best-fitting
classification tree had only one node. This provided
f u r t h e re v i d e n c ea g a i n s tt h ep r e s e n c eo fm a j o re p i s t a t i c
associations being in effect among the SNPs from the
candidate genes under study.
While the evidence for epistasis among the candidate
SNPs is not strong, our analysis supports the concept
that considering the broader collection of a large num-
b e ro fS N P sd o e sp r o v i d ea dditional insight into the
genetic control of rubella antibody levels. By assessing
a l lS N P si nas i n g l em o d e lw ew e r ea b l et oi d e n t i f ya
broader collection of candidates than was possible when
each SNP was considered individually. While the uni-
variate tests implicated SNPs in the LTA, IL6 and IL4R
genes, the analysis of all SNPs identified not only these
genes but also a broader collection of genes that appear
to contribute to variation in rubella antibody levels. The
29 SNPs that were jointly associated with humoral
immunity are shown in Table 2. These SNPs that were
jointly associated with differences in rubella antibody
levels resided in a total of 23 genes.
While there is evidence in favor of there being a major
genetic component to the observed levels of rubella-
specific antibodies following vaccination [3], the current
knowledge of the genetic control of immune responses
to rubella immunization has been obtained from studies
that focused on a small number of genetic loci that
were analyzed one at a time [7-9,11-14]. Given the
genetic diversity required by the immune system to
mount an adequate response to a wide number of
pathogens, it is likely that these one-at-a-time
approaches are inadequate for the comprehensive study
Figure 2 Quantile plot of observed versus expected p-values
(on the logarithmic scale) for the associations between the
combinations formed from each possible pair of SNPs and
rubella antibody levels. While the observed p-values depart
somewhat from the line of unity, they do not follow a pattern that
suggests the presence of major epistatic effects.
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the efforts reported here implicated a broader number
of candidate genes as potentially being involved in mod-
ulating rubella-specific antibody levels using multigenic
analyses that examined more than one locus at a time.
The genes that have been implicated as being asso-
ciated with rubella antibody levels were selected for
study because of their general relevance to viral immu-
nity. The humoral immune response to rubella vaccine
reflected in assayed antibody levels is the cumulative
result of the actions and interactions of multiple genes
and pathways. Those SNPs that were identified as being
important for humoral immunity to rubella are included
in Table 2. Among these genes are cytokine (Th1/Th2/
inflammatory) and cytokine receptor, lymphotoxin alpha
(LTA), leukocyte specific transcript-1 (LST1), antiviral
effector (OAS2), IFN-type I-induced (EIF2AK2), adeno-
sine deaminase (ADAR), vitamin A receptor family
(RARB), the innate antiviral factor (TRIM5 and
TRIM22), mucin-like protocadherin (MUPCDH) and
other genes. These identified variants reside in genes
spanning a broad collection of different classes of
immune-related genes. Since genetic polymorphisms
may function jointly to determine the outcome of vac-
cine-induced antibody response, it is reasonable to sug-
gest that the observed antibody level effects in our study
may be an outcome of combinations of SNP-defined
alleles and immune response pathways, with the cumu-
lative sum of variants across these genes influencing
levels of rubella-specific antibodies. Better understanding
the immunogenetic impact of multiple gene family path-
ways critical to development of humoral immune
responses following rubella vaccination may provide
insight into the factors that influence rubella immunity.
Strengths and Limitations
This manuscript outlines the first analysis of its kind, an
assessment of the associations between a large collection
of SNPs from immunologically relevant genes and
rubella antibody levels. This analysis made it possible to
examine all SNPs we genotyped on a well-characterized
cohort of study participants and assess the likelihood
that the univariate SNP results were significant on their
own. This examination also ma d ei tp o s s i b l et os t u d ya
variety of types of associations between candidate SNPs
and rubella antibody levels, both epistatic and otherwise.
When complicated analytical approaches were
employed, we used resampling methodologies to obtain
statistical significance levels that were not over-trained
to the data [39]. This study does have two important
limitations, however. First, as with all genetic association
studies there is a need for replication, and a replication
cohort is currently unavailable to us. Second, there was
limited power to detect significant epistatic associations;
for two SNPs with MAFs of 0.15 there was 80% power
to detect interactions if the effect of carrying one copy
of each of the minor alleles was associated with a 1.8-
fold departure from additivity, while the detectable effect
for a main effect for these SNPs was for a 1.25-fold dif-
ference. An additional limitation of this study is that our
analyses were restricted to a collection of 726 tagSNPs
identified from 84 candidate genes. There are likely to
be other genetic variants that contribute to differences
in rubella antibody levels that we have not assessed.
Conclusion
The implications of this work are two-fold. First, it pre-
sents a novel methodological approach that can provide
additional insights into candidate genetic associations
when analyzing similar data in other studies. When
searching for associations between genes that are part of
a complex system and outcomes that are potentially
influenced by genetic variation in this system, it is
important to consider more than just simple single-SNP
assessments. Second, it is clear that the “dominant
allele” model of genetic regulation of complex system
processes such as immune response is both uncommon
and too limiting. At least for those viral vaccines we
have studied (measles, mumps, rubella, vaccinia and
influenza), variation in immune responses are clearly the
result of small contributions from many genes and sets
of genes acting in concert. These data provide motiva-
tion to move beyond simple univariate associations to
the types of analyses illustrated in this report in order to
identify significant multigenic associations otherwise
u n o b s e r v a b l eb ys i m p l eu n i v a r i a t em o d e l s .T h ev a l u eo f
approaches such as this include the ability to more
clearly identify and model the genetic determinants of
immune response to viral vaccines. The findings from
these models can then be used to inform the develop-
ment of next-generation vaccines.
Methods
Study subjects
The characteristics of the 738 healthy children and
young adults (age 11 to 19 years) who participated in
this study have previously been described [40]. Study
subjects were immunized with two age-appropriate
doses of live measles-mumps-rubella-II (MMR-II) vac-
cine containing the Wistar RA 27/3-strain of rubella
virus. The study participants were residents of Olmsted
County, Minnesota, a community where no case of
rubella infection had been reported during their life-
times. The majority of the study population was white
(91%), with 47% being female, with a median age at
enrollment of 15 years (Table 1). The median age at the
first and second immunization were 15 months and 11
years, respectively, and the median time between last
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While 738 children and young adults were enrolled in
the study, after exclusion for genotyping quality a total
of 714 subjects were retained for analyses in this study.
The Mayo Clinic Institutional Review Board granted
approval for the study, and written informed consent
(parental permission and assent for minors) was
obtained.
Humoral Immunity Assays
Rubella-specific IgG antibodies after two doses of the
rubella vaccine were detected in serum by a whole
rubella virus-specific chemiluminescent immunoassay
(Beckman Coulter Access, Fullerton, CA) according to
the manufacturer’s instructions. The limit of detection
for this assay was 0.5 IU/ml and the coefficient of varia-
tion in our laboratory was 6%.
TagSNP selection
We selected a total of 768 tagSNPs from 84 candidate
genes encoding cytokines and cytokine receptors. The
details of SNP selection have described previously [12].
Briefly, we generated a list of SNPs within, and 10 kb
upstream and downstream of, the targeted candidate
genes using the Hapmap Phase II (http://www.hapmap.
org)[41], Seattle SNPs (http://pga.mbt.washington.edu/)
[42], and NIEHS SNPs (http://egp.gs.washington.edu/)
[43] as source databases. We included SNPs that had
validation data, successful predictive genotyping scores
for Illumina GoldenGate assays, and reported minor
allele frequencies (MAF) ≥0.05 in the list of possible
SNPs. We used the linkage disequilibrium (LD) based
ldSelect algorithm [44] to identify tagSNPs from the
initial list with pairwise LD threshold of r
2 <0.90 for Cau-
casians. Using these criteria, we selected 768 potential
SNPs in our candidate genes of interest (see Additional
file 1). We used the nomenclature described by den Dun-
nen and Antonarakis for all genotype variants [45].
Genotyping methods
Our genotyping methods were previously described in
detail [17]. Briefly, genomic DNA samples (n = 738, 250
ng each) obtained from frozen blood clots using the Pure-
gene extraction kit (Gentra Systems Inc., Minneapolis,
MN) were genotyped for 768 candidate SNPs using a cus-
tom designed 768-plex Illumina GoldenGate™ assay (Illu-
mina Inc., San Diego, CA), following the manufacturer’s
instructions [12]. All the SNPs selected for the custom
Illumina panel had design scores >0.4. A Coriel Trio DNA
(mother: NA11875, father: NA10859, daughter: NA10858)
and two other genomic DNA controls were used as stan-
dards to review and refine clustering. These controls were
genotyped on each plate, which allowed us to assess geno-
typing concordance of replicate subjects.
We used PCR-based TaqMan assays (Applied Biosys-
tems, Foster City, CA) as the secondary platform to gen-
otype SNPs that failed genotyping on the Illumina
platform. All assays were performed according to the
manufacturer’s instructions, and the results were ana-
lyzed on the ABI Prism 7900 using Sequence Detection
Software (Applied Biosystems).
Illumina 10% GenCall scores >0.4 and call rates >90%
were used as thresholds for the initial laboratory quality
control. The data from genotype calls made by BeadStu-
dio 2 software were transferred to SAS for further analy-
sis, where call rates for each subject, and for each SNP,
were estimated. Participants’ genotypes were used to
estimate allele frequencies for each SNP, and departures
from Hardy-Weinberg equilibrium (HWE) were assessed
using a Pearson goodness-of-fit test or, for SNPs with a
minor allele frequency of less than 5%, a Fisher exact
test [46].
Statistical methods
T h ep u r p o s eo ft h ee f f o r t sr e p o r t e dh e r ew a st od e t e r -
mine the multigenic contributions of SNPs from the
candidate genes involved with immunity that were
selected for this study. Prior to performing statistical
comparisons, the characteristics of study participants
were categorized and examined in relationship to the
measured rubella-specific IgG antibody levels (repre-
sented as IU/ml). The median, and the 25
th and 75
th
percentiles, of the antibody levels were summarized
overall, and for the categories of the descriptive vari-
ables. Comparisons of the antibody levels across the dif-
ferent categorizations of the descriptive variables were
achieved via analysis of variance (ANOVA), with rubella
antibody levels being analyzed on the logarithmic scale
to correct for data skewness. All analyses were adjusted
for the following set of covariates potentially associated
with the measured rubella-specific antibody titers: age at
enrollment, race, gender, age at first rubella vaccination,
age at second rubella vaccination, and cohort status.
While the focus of this effort was on the multigenic
contributions of these SNPs to variation in rubella-spe-
cific antibody levels, a test of association was obtained
for each genotyped SNP that met quality control criteria
in our study subjects to examine the ordinal genetic
association between each of the SNPs of interest while
adjusting for the descriptive variables using linear
regression. A quantile plot of the overall distribution of
single-SNP p-values was extracted and summarized for
all SNPs.
The primary interest was to identify the degree to
which combinations of SNPs might provide novel
insight into the potential control of rubella-specific anti-
body levels. Therefore, a series of multigenic analyses
were carried out. We first assessed the degree to which
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levels of rubella-specific antibody titers. We applied two
approaches to identify these multi-allelic associations.
The first was a single omnibus test of association where
we identified the positively associated allele of each SNP
and tallied the number of positively associated alleles of
the candidate SNPs within each individual and assessed
the association between this count variable and rubella
antibody levels while controlling for the descriptive vari-
ables. The second approach again forced the inclusion
of descriptive covariates, but relied on a stepwise model
selection paradigm for identification of SNPs to be
included. In this stepwise process, we added or removed
as i n g l eo r d i n a lS N Pv a r i a b l ea tat i m eu n t i lo n l yS N P s
that contributed to an association with rubella antibody
levels remained in the regression model, using p-values
for entrance or removal of 0.05. For each of these meth-
ods, we applied randomization tests to account for the
fact that we identified the “positively associated allele”
for each SNP within the same dataset in which we were
performing the test of significance, and to account for
the model selection approach we used to identify the
model of candidate SNPs [39]. These randomization
procedures rely on repeated random re-assignment of
observed antibody levels to model the situation where
there is no association between SNPs and phenotype.
These repeated randomization data sets are then used to
perform the analyses that were carried out on the origi-
nal data. The resulting p-values from these randomized
data sets are then used to obtain an empirical estimate
of the null distribution of p-values. The final randomiza-
tion p-value reflects how extreme the observed p-value
is, relative to this null empirical distribution.
In order to search for potential combinations of SNPs
that were jointly associated with antibody levels, we
applied the approach advocated by Marchini et al [38],
in which we enumerated all possible combinations of
the genotypes observed for each pair of candidate SNPs
and tested for differences in the log-transformed rubella
antibody levels among these categories using linear
regression methods while adjusting for the descriptive
variables. After performing this test for each of the
263,175 pairs of candidate SNPs, we produced a quantile
plot to summarize the difference between the observed
p-value distribution and p-value distribution that would
have been expected if there were no pairs of SNPs that
were significantly associated with antibody levels.
Additionally, we used recursive partitioning techniques
to search for potential higher-order interactions among
the candidate SNPs that might influence the observed
levels of rubella-specific antibody levels. For a quantita-
tive phenotype, these methods recursively search for
optimal combinations of splits of explanatory variables
such that the differences in the average levels of the
phenotype among the identified groups are maximized
[47,48]. We utilized the recursive partitioning routines
available in S-Plus (TIBCO Software Inc., Palo Alto, CA)
to perform these assessments. All statistical tests were
two-sided and, unless otherwise indicated, analyses were
carried out using the SAS software system (SAS Insti-
tute, Inc., Cary, NC).
Additional material
Additional file 1: Supplementary Table: Genes included in the
analysis, along with the numbers of genotyped SNPs of various
types.
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